



Amgen Names Arvind Sood Vice President, Investor Relations

September 16, 2004

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 16, 2004--Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology company, today announced the appointment of Arvind Sood to the position of vice president, Investor Relations. Sood will be responsible for developing, implementing and managing a comprehensive and strategic global investor relations program.

"Arvind brings more than 20 years of domestic and international pharmaceutical industry experience to Amgen," said Richard Nanula, Amgen's executive vice president and chief financial officer. "I am confident that he will be a great asset in effectively communicating to Amgen's investment audiences."

Sood joins Amgen from Aventis S.A. where he served as senior vice president for Investor Relations and Financial Communications and was responsible for overseeing global investor relations activities for the company. Sood also worked at Rhone-Poulenc S.A, before Rhone-Poulenc's merger with Hoechst A.G. to form Aventis, where he progressed through positions of increasing responsibility in investor relations including his role of senior vice president, Investor Relations and Financial Communications. Prior to his tenure at Aventis and Rhone-Poulenc, Sood spent more than 12 years at the Upjohn Company of Kalamazoo, Michigan, where he served in several functions including pharmaceutical sales, marketing and investor relations.

Sood was recognized as the "Best IR Professional" in 2004 amongst all European pharmaceutical companies by Institutional Investor and commended in 2002 by IR Magazine for "Best Investor Relations by a European Company in the U.S. Market." He obtained his undergraduate degree in Business Administration from Western Michigan University and his master's degree in Business Administration from the Graduate School of Business at Central Michigan University.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.

CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-4587 (media)
Laura Biswas, 805-447-1060 (investors)

SOURCE: Amgen